Galapagos said it would supply the small molecule compounds to Johnson & Johnson Pharmaceutical research and development division of Janssen Pharmaceutica.
The company said the agreement was a natural expansion of its drug discovery relationship with Johnson & Johnson.
Under the terms of the two-year collaboration, BioFocus DPI will provide access to compounds from its SoftFocus small molecule libraries and will also generate customer specific compound library sets for use in J&J's drug discovery programs. Financial terms of the deal were not disclosed.